FDA Approval Alert: The Need-to-Know | Asciminib in Ph+ Chronic Myeloid Leukemia in Chronic Phase

In October 2024, the FDA granted accelerated approval to asciminib as a therapy for adults with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.
FDA Grants Accelerated Approval to Asciminib in Ph+ CML in Chronic Phase
Article
Oct 29, 2024 6:04 PM
Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.